Study examines the relationship between outcomes and delay
Durvalumab monotherapy appears safe and well-tolerated
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy